Wegovy cost without insurance 2026: the real cash-pay paths

TLDR. The list price of Wegovy is $1,349 per month. Almost no cash-pay patient pays it. The four real routes in 2026: NovoCare Pharmacy direct at $349 to $499 per month for all doses, Hims & Hers branded Wegovy at $199 introductory and $299 to $399 maintenance, telehealth programs that route through NovoCare with a membership layer on top, and a fading compounded path now restricted to medical-necessity exceptions. Year one all-in lands between $2,400 and $6,000 depending on which route, with NovoCare direct at $349 the cheapest non-compounded option for most patients.

Wegovy's list price (the wholesale acquisition cost, or WAC) is $1,349.02 for a one-month supply at any dose. The number is real. It appears on pharmacy benefit manager formularies, on hospital purchase invoices, and on the headline of every news article about GLP-1 affordability. It is also almost completely fictional for the cash-pay patient.

Cash-pay Wegovy patients in 2026 do not walk into a pharmacy and pay $1,349. They take one of four routes, each with a different price band, a different friction profile, and a different sustainability over twelve months.

Route 1: NovoCare Pharmacy direct

Novo Nordisk launched NovoCare Pharmacy in early 2025 as the cash-pay channel for patients without coverage. The patient gets a Wegovy prescription, sends it directly to NovoCare, and pays one of two flat prices: $349 per month for the 0.25 mg and 0.5 mg titration doses, $499 per month for the 1.0 mg, 1.7 mg, and 2.4 mg maintenance doses.

NovoCare ships a 28-day supply (four pens) to the patient's home. No insurance involvement. No prior authorization. No pharmacy benefit manager. The patient pays Novo Nordisk directly through the NovoCare portal.

Year-one math at NovoCare direct, assuming a standard 16-week titration to 2.4 mg:

• Month 1 (0.25 mg): $349
• Month 2 (0.25 mg): $349
• Month 3 (0.5 mg): $349
• Month 4 (0.5 mg): $349
• Month 5 (1.0 mg): $499
• Month 6 (1.0 mg): $499
• Months 7 through 12 (1.7 to 2.4 mg): $499 each
• Year-one total: $4,988 to $5,988

That is the cheapest non-compounded path to a real branded Wegovy prescription in the United States in 2026.

Route 2: Hims & Hers branded Wegovy

In March 2026, Hims & Hers announced a Wegovy distribution partnership with Novo Nordisk as part of the broader settlement that ended Hims's compounded semaglutide business. The deal sets bundled cash-pay pricing inside the Hims platform: $199 for month one, $299 per month for ongoing 1.0 mg, $399 per month for 1.7 mg and 2.4 mg maintenance.

The Hims bundle includes the medication, the telehealth visit, the prescription, and shipping. The patient does not interact with NovoCare. They sign up at Hims, take an asynchronous medical assessment, and the medication ships from the partner pharmacy.

Year-one math at Hims:

• Month 1: $199
• Months 2 through 4 (0.5 to 1.0 mg): $299 each
• Months 5 through 12 (1.7 to 2.4 mg): $399 each
• Year-one total: $4,288

Hims comes out roughly $700 cheaper than NovoCare direct over 12 months, with the tradeoff of being locked into the Hims clinical layer rather than working with an independent prescriber. The telehealth experience is asynchronous (chat only) and the GI side-effect coaching is lighter than at a dedicated obesity-medicine program.

Route 3: Telehealth membership plus NovoCare

Most weight-loss telehealth programs that prescribe Wegovy in 2026 (Ro, PlushCare, Noom Med, Calibrate) route the prescription through NovoCare and charge a separate membership fee on top.

The math is additive. A patient at Ro Body on the annual plan pays $74 per month for the membership plus $349 to $499 per month to NovoCare for the medication. All-in: $423 to $573 per month, year-one total $5,400 to $6,400.

The question this route forces: what does the membership buy? Honest answers are real clinical follow-up, GI side-effect coaching, dose-titration adjustments, and a prescriber the patient can message. Less honest answers are software polish and a logo. The category varies by program; we score it on the comparison chart.

Route 4: Compounded semaglutide (fading path)

Compounded semaglutide at Mochi and a few smaller programs continues to exist at $99 to $199 per month all-in, but the regulatory ground has shifted hard. The FDA declared the semaglutide shortage resolved in October 2024. The Hims-Novo settlement in March 2026 set the template for manufacturer litigation against compounders. Several 503A pharmacies have been shut down for sterility failures specific to GLP-1 production.

The path still works for some patients today. It is not a path a patient should assume will exist in twelve months. Year one at $150 per month is real money saved, but the patient needs a transition plan to NovoCare or branded coverage if compounded supply halts.

See our deeper analysis of compounded semaglutide safety and the FDA position for the full regulatory picture.

The savings card almost no cash-pay patient can use

Novo Nordisk offers a manufacturer savings card for Wegovy that caps the patient cost at $0 per month for the first 12 months if Wegovy is covered by commercial insurance and at $225 off per month if Wegovy is on a commercial plan but not covered.

The two structural exclusions: federal payers (Medicare, Medicaid, Tricare, VA) are ineligible, and patients with no insurance at all are ineligible. The savings card is for commercially insured patients with imperfect coverage, not for the cash-pay segment this article is about. We mention it because patients routinely find the savings card before they understand it does not apply to them.

When insurance is worth fighting for

For patients with commercial insurance that excludes Wegovy on the formulary, the cost-benefit of a prior authorization appeal depends on three variables: the patient's plan tier, the qualifying medical history, and the time available.

Patients with established cardiovascular disease (prior MI, stroke, or symptomatic peripheral artery disease) have a substantially stronger PA case after the FDA approved Wegovy for cardiovascular event reduction in March 2024 on the back of the SELECT trial. SELECT showed a 20 percent reduction in major adverse cardiovascular events over a mean 39-month follow-up in patients with established cardiovascular disease and BMI 27 or higher, without diabetes (Lincoff et al, NEJM 2023). Plans that previously denied Wegovy for weight management often cover it under the CV indication.

Patients with type 2 diabetes have a separate path: Ozempic (also semaglutide) is on most plans for T2D, and Wegovy is sometimes covered after a step through Ozempic.

The honest threshold: if a PA appeal has a realistic path under a covered indication, the year-one savings are roughly $4,000 to $5,000 versus cash-pay routes. If the appeal is purely "obesity without comorbidities" on a plan that excludes obesity drugs, the appeal usually loses. See our prior authorization letter generator for the template language.

Year one compared across the four routes

The spread between cheapest and most expensive non-compounded route is roughly $2,100 per year. For a patient committing to a multi-year therapy, the route choice compounds.

What "no insurance" actually means at the pharmacy

Patients who arrive at a retail pharmacy with a Wegovy prescription and no insurance card will be quoted somewhere between $1,300 and $1,500 per month at most chains. This is the WAC plus the pharmacy's margin. It is essentially never the right path.

The patient should not fill the prescription at the retail pharmacy. Instead, they should ask the prescriber to route the prescription to NovoCare directly, which costs $349 to $499, or to a telehealth program that bundles. The retail pharmacy retail price exists primarily as a reference point for insurance reimbursement, not as a real cash-pay channel.

What changes in late 2026

Generic semaglutide is expected to enter the United States market in late 2026 or early 2027, contingent on ANDA approvals. The likely price floor for a generic injectable semaglutide is $50 to $150 per month based on patterns in markets where generic GLP-1s have already launched.

If generic semaglutide reaches the US at $100 per month, the entire economics of cash-pay Wegovy resets. NovoCare direct at $499 becomes uncompetitive against a generic at $100. Hims at $399 becomes uncompetitive. Compounded at $150 stops having a price advantage.

Patients starting Wegovy in mid-2026 should plan to revisit the cost picture in 12 months. The current route may not be the right route a year from now.

Frequently asked questions

Why is Wegovy so expensive in the United States?

Two reasons. First, the development cost: Novo Nordisk spent more than a decade and several billion dollars developing semaglutide for obesity. The price reflects recovering that investment plus profit. Second, US pricing structurally exceeds European pricing because the US lacks single-payer price negotiation. Wegovy retails in the UK at roughly £175 per month and in the EU at €200 to €300, against a US list of $1,349. The chemistry is identical.

What is the cheapest legal way to get real branded Wegovy in 2026?

Hims & Hers at $199 for month one and $299 to $399 maintenance is the cheapest non-compounded bundled path. NovoCare Pharmacy direct at $349 to $499 is the cheapest unbundled path. Both supply real Wegovy with Novo Nordisk batch oversight. Patients with commercial insurance and a qualifying indication can pay $0 to $50 per month through prior authorization, which is cheaper than any cash route.

Does the NovoCare savings card work without insurance?

No. The Wegovy savings card requires commercial insurance. Federal payer patients (Medicare, Medicaid, Tricare, VA) and patients with no insurance are not eligible. The cash-pay alternative is NovoCare Pharmacy direct at $349 to $499, which is a separate program.

Is the $1,349 list price ever what a patient actually pays?

Almost never. The list price (WAC) is the wholesale acquisition cost paid by pharmacies and pharmacy benefit managers. Cash-pay patients have access to NovoCare direct at $349 to $499, telehealth bundled pricing at $199 to $399, and compounded paths at $99 to $199. A retail pharmacy will quote the WAC plus markup to an uninsured walk-in, but no patient should fill at that price.

How much will Wegovy cost when generic semaglutide launches?

Likely $50 to $150 per month for a generic injectable based on international pricing patterns where generic GLP-1s have already launched. Generic semaglutide is expected in the United States in late 2026 to early 2027, contingent on ANDA approvals at FDA. The Wegovy brand will probably maintain a price premium for two to three years post-generic before settling toward generic pricing.

Is compounded semaglutide worth the savings in 2026?

It depends on the patient's tolerance for supply uncertainty. Compounded at $99 to $199 per month saves $3,000 to $4,000 per year against NovoCare. The molecule is the same. The risks are documented batch quality issues, occasional supply interruptions, and the possibility that the regulatory path closes entirely. Patients on compounded should have a transition plan to NovoCare or branded coverage if their pharmacy shuts down. See our compounded safety analysis for the full picture.

Does Medicare cover Wegovy for weight loss?

No. Medicare Part D is statutorily barred from covering anti-obesity medications. Wegovy is covered under Medicare only for the cardiovascular indication after the March 2024 FDA approval expansion: patients with established cardiovascular disease and BMI 27 or higher can access Wegovy through Medicare Part D. The exclusion for pure weight management remains in place. Cash-pay Medicare patients use the same NovoCare direct route as commercial-uninsured patients.

Will my employer plan cover Wegovy?

Roughly 55 to 60 percent of large employer commercial plans covered Wegovy in some form in 2025, with most requiring prior authorization. The coverage rate has dropped each year as employers face premium pressure from GLP-1 utilization. Smaller employer plans and ACA marketplace plans cover Wegovy less often. Check the formulary tier before assuming coverage. If Wegovy is on tier 3 or 4 with a coinsurance percentage rather than a flat copay, the patient cost can exceed cash-pay NovoCare direct.

Citations

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021;384:989-1002. nejm.org/doi/full/10.1056/NEJMoa2032183
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232. nejm.org/doi/full/10.1056/NEJMoa2307563
• Novo Nordisk. NovoCare Pharmacy direct cash-pay program. novocare.com/wegovy
• FDA. Wegovy (semaglutide) prescribing information and labeling. accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• Centers for Medicare and Medicaid Services. Part D coverage of anti-obesity medications policy statement, March 2024 update. cms.gov/files/document/clarification-medicare-part-d-coverage-anti-obesity-medications-aoms.pdf
• Kaiser Family Foundation. An Overview of the Medicare Part D Prescription Drug Benefit. 2025. kff.org/medicare/issue-brief/an-overview-of-the-medicare-part-d-prescription-drug-benefit/